Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo’s Tres Cantos Open Lab Trawls For Answers To Neglected Diseases

Executive Summary

Tres Cantos, Spain facility hopes to move molecules into clinical research in 2013/2014. Wellcome Trust has just pledged £5 million to help support the lab’s open R&D programs.

You may also be interested in...



Corporate Responsibility With Teeth: GSK’s Developing Countries Unit

Initiative to build health care infrastructure and create a sales channel for GSK medicines is starting to yield tangible results.

AZ Restructures, But Will Changes Sideline Plans To Accelerate R&D?

AstraZeneca unveiled an R&D restructuring March 18 that will consolidate research to three locations and reduce headcount by 1,600, but the company will have to be dogged in its effort to relocate key employees if it is to ensure the changes don’t disrupt its broader goal of accelerating the pace of R&D.

GSK's Open Lab Looking To Synch Big Pharma Neglected Disease Initiatives

Tres Cantos lab's initial focus is on on malaria, tuberculosis, and kinetoplastid diseases.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel